Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 400 mg/Day Lacosamide Tablets in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome

NCT00401830 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00401830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00401830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 400 mg/Day Lacosamide Tablets in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
February 29, 2008
Enrollment
159 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

fibromyalgia syndrome